ESMO 2023

Preoperative checkpointinihition in ER+ disease

DATO-DX - where is it going?

Remarkable efficacies in patients with HER2+ mBC with brain metastases

Highlights in eBC

5 year follow-up

My highlights of ESMO23 in metastatic breast cancer

The FGFR story in bladder cancer at ESMO23

When the history of ADC is written: Redefining first-line standard of care in mUC!

Clearing up non-clear cell RCC

Early use of enzalutamide in advanced prostate cancer

Lu-PSMA leads forward

New 3rd line therapy for RCC

ALINA - immediate change of practice!

Tarlatamab in SCLC

My highlights from ESMO 2023

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Data updates for CDK4/6 inhibitors in EBC at ESMO23 - implications for clinical practice

What is your definition of triple-negative breast cancer?

Anticipated updates and exciting new data for checkpointinhibitors

What was the most exciting news at ESMO23?

New and better biomarkers are needed!

Negative EFS results from NeoTrip

Carry-over effects in monarchE confirmed

Clinically relevant effect of pembro also in PCR

MonarchE - trial update

Our guidelines are correct

Ribociclib effective in all subtypes

Analysis of tumour microenvironment and immunophenotype in TNBC

Preoperative checkpointinihition in ER+ disease

Pembrolizumab solidifies as SOC in early-stage TNBC

Neoadjuvant IO - is their new strategy in HR+ breast cancer

Metabolomics reveal differential expression of OMEGA 3 & OMEGA 6 in neoadjuvant treatment

My highlights of ESMO23 in early breast cancer

Use of immunotherapy in the perioperative setting of luminal Her2- BC

Immunoncology in eBC - triple negative and more?

New data on neoadjuvant immunotherapy

ER-low corresponds diagnostically to ER-0 breast cancer

5 year follow-up

HR+ study with > 20 % PCR

Detailed view of nodal-negative patients

Consolidation of data in early HR+ and triple-negative breast cancer

Highlights in eBC

Prognostic score in early HR+/HER2-BC: translational data from ADAPT

La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6 nel condizionare la risposta alla terapia neo-adiuvante

MonarchE - mise à jour de l'essai

Studio NeoTrip: negativi i risultati

Nouvelles données sur l'immunothérapie néoadjuvante

Punti salienti in eBC

What was the most exciting news at ESMO23?

ADCs in HER2+, HER2low and TNBC - what is the future of ADCs?

Improvement of therapy outcome by app-based patient education

New ADC for metastatic breast cancer?

How to organize a molecular tumorboards in breast cancer?

New targets, new linker, new ADCs - much more to learn with new therapies!

TULIP: Trastuzumab duocarmazine without OS benefit

ADC + Immunotherapy - the BEGONIA study paradigm

Dato-DXd - new player in advanced luminal disease

My highlights of ESMO23 in metastatic breast cancer

OP seems to be dispensable for super responders

OP-1250 (Palezestrant) confirms the role of SIRDs after CDK4/6i

Even more new generation ADCs in breast cancer?

New ADC in HR+ disease

Abemaciclib remains consistent in 5-year follow-up

Improved oncological therapy with the smartphone

T-DXd in HER2+ patients with brain metastases

TROP2 expression as a potential mechanism of resistance in HER2+ patients

Our guidelines are correct

Robust data from the monarchE

Duvalumab + Dato-DXd effective

HS20089 - a novel ADC is coming for TNBC

HER2DX in the PHERgain trial

Remarkable efficacies in patients with HER2+ mBC with brain metastases

Still on track for success in HER2-low MBC

Patient-centered molecular medicine - a new approach

T-DXd - new standard of care for brain mets?

Benefit for SG even after intensive pretreatment

Can surgery be spared following primary systemic therapy?

Highlights in mBC

T-DXd also effective for brain metastases

DATO-DX - where is it going?

Fulvestran better than anastrozole, but no survival benefit

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei SERDs dopo le cicline

La expresión de TROP2 como potencial mecanismo de resistencia en pacientes HER2+.

HER2DX en el estudio PHERgain

HS20089 - un nuovo ADC che si affaccia sulla scenda del TNBC

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym leczeniu systemowym?

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

Lo studio BEGONIA nelle paziento con tumore triplo negativo

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par le cancer triple negative

Punti salienti in mBC

T-DXd - nowy standard postępowania w przerzutach do mózgu?

Targeted therapy will move forward - but more robust data is needed.

What is the future of immune therapy in prostate cancer?

Should we use zoledronic acid in all ADT patients?

The optimal timing of RT after radical prostatectomy and QoL data of ENZA therapy in nmHSPC

Combination of radioligand therapy with chemotherapy useful

Embark without fear

STAMPEDE. Bone prediction not for everyone - better risk stratification for PCa

Lu-PSMA leads forward

IO therapy in metastatic prostate cancer.

Brave New World in mCRPC

TITAN: ultra-low PSA = best prognosis

Osteoprotection at mHSPC

EMBARK expands ENZA indication to PCa

Precision medicine at mCRCP

Salvage radiotherapy the new standard

EMBARK - Quality of Life

ENZA P:Trial and controversies

RADICALS RT: Trial and controversies

PSMAfore unleashes urooncologic opportunity

PSMA FORE: Trial and controversies

When immunotherapy is probably not the best choice: The case of untreated metastatic prostate cancer

Big data and AI prediction tools

Longterm toxicity of adjuvant RT after prostatectomy

Early use of enzalutamide in advanced prostate cancer

CXCR2 inhibitor in PCa

Immunotherapy in metastatic PCa

Negative data for pembrolizumab in mHSCPC & mCRPC

CXCR2 hämmare och prostatacancer

EMBARK och livskvalitet

Big Data och AI för prediktion vid prostatacancer

STAMPEDE data. Skelettstärkande och riskstratifiering.

Immunterapi vid prostatacancer

Cuando la inmunoterapia probablemente no es la mejor elección: El caso del cancer de próstata avanzado en pacientes no seleccionados

FGFR inhibitors and ADC combinations in urothelial cancer - new options for the future?!

Part 2: New standard of care in first line urothelial cancer!

Part1: New standard of care in first line urothelial cancer?!

New SoC in firstline bladder cancer

The FGFR story in bladder cancer at ESMO23

FGFR inhibitors: What is the best scenario for this family of compounds?

Chemo-IO establishes itself in the first-line treatment of bladder cancer

Unique bladder delivery system of gemcitabine herolds remarkable response

Amazing new data in bladder cancer

DAD, DAD-IO

EV + Pembro as standard of care in first-line therapy of bladder cancer

When the history of ADC is written: Redefining first-line standard of care in mUC!

Στιγμιότυπα για τον καρκίνο των νεφρών και της ουροδόχου κύστης στο ESMO23

Inhibidores de FGFR: Cual es el mejor escenario para esta familia de fármacos?

Reescribiendo la historia de una enfermedad: Nuevo estándar de tratamiento en primera linea en cancer urotelial avanzado

L'histoire du FGFR dans le cancer de la vessie à l'ESMO23

Is de-escalating therapy ready for prime-time?

Important new treatment option but only for subset of patients?

Where does the future therapy go in renal cell carcinoma?

Kidney cancer highlights at ESMO23

Clearing up non-clear cell RCC

Belzutifan - whats next kidney cancer?

New mode of action in mRCC - ready for prime time?

Belzutifan in later lines of therapy

New 3rd line therapy for RCC

Intermittent therapy also possible with TKIs

Moving patients to the neoadjuvant setting in non-metastatic NSCLC

ALINA - remarkably positive DFS in early-stage ALK+ NSCLC

Neoadjuvant chemo-immunotherapy new standards in early & advanced NSCLC

ALINA - immediate change of practice!

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

Substantial improvement in local regional NSCLC

Big improvements in early stage and a subset of metatstic NSCLC

Adjuvant alectinib in patients with early-stage ALK+ NSCLC

Perioperative IO: OS-benefi from KEYNOTE-671

My highlights from ESMO 2023

Circulating DNA in AEGEAN trial

Scene is set for inductive immunotherapy

ALINA - a new paradigm in operated NSCLC with ALK-fusion

I miei punti salienti di ESMO 2023

Les points forts de l'ESMO 2023

ALINA - un nouveau paradigme dans cBNPC avec la fusion ALK

Perioperatieve chemo-immunotherapie voor alle patienten met resectabel stadium II-IIIB NSCLC?

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

Activating EGFR-mutation - what's coming up?

ESMO2023-impact on everyday practice!

Evolving landscape of ADCs

Rare oncogenic alterations: landmark results on exon 20 insertion & confirming data on RET fusion+ NSCLC

My highlights from ESMO 2023

Does immunotherapy still have a place in EGFR-positive mNSCLC?

PAPILLON - bringing together therapy for the 1st line

Amivantamab upfront? MARIPOSA trial

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

Practice changing results on exon 20 insertion mNSCLC

Substantial improvement in rare alterations

Adagrasib + pembrolizumab in patients with KRASG12C mutation

Changing treatment landscape in EGFR-mutated NSCLC

NRG fusions: a new drugable target?

Brain metastases – options to improve the systemic treatment

By unanimous decision and still the champion – docetaxel!

New standard of care for metastatic EGFR exon 20 insertion mutated NSCLC

Do ADCs have brain activity?

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

TROPION-Lung01: positive development

Big improvements in early stage and a subset of metatstic NSCLC

MARIPOSA II: Trial and controversies

Amivantamab at progression? MARIPOSA-2 trial

Treatment sequences for EGFR-mutated Patients

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

LIBRETO - a positive study, but was it necessary?

MARIPOSA: Trial and controversies

Heeft immunotherapie nog een plek in de behandeling van EGFR-positief gemetastaseerd NSCLC?

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Nieuwe standaard voor gemetastaseerd EGFR exon20 insertie gemuteerd NSCLC

Les points forts de l'ESMO 2023

Veränderte Behandlungslandschaft bei EGFR-mutiertem NSCLC

L’amivantamab, nouveau standard de traitement pour les EGFR exon 20

Quelles séquences thérapeutiques pour les patients EGFR mutés

Amivantamab upfront? MARIPOSA trial

I miei punti salienti di ESMO 2023

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

Amivantamab at progression? MARIPOSA-2 trial

Impact of T-cell engagers in SCLC

A new option in relapsed SCLC

Tarlatamab in SCLC

New hope for patients with SCLC

Neue Hoffnung für Patienten mit SCLC

First data on luveltamab in multiline treatment for endometrial cancer

New data on H&N Cancer

Update on gynaecological cancers

Precision oncology in CUP

New data on sarkomas

Evolution of the revolution - the RUBY trial

PCO Therapeutics